Hypersensitivity Reactions

  • Maged S. Mikhail
  • Delbert R. Black

Abstract

Egyptian hieroglyphics describe the sudden death of a pharaoh following a wasp sting in 2640 BC, possibly the first recorded account of an anaphylactic reaction (1,2). Anaphylaxis is the most extreme, life-threatening systemic manifestation of a hypersensitivity reaction that occurs in a sensitized host who is re-exposed to an inciting antigen. The yearly incidence of anaphylactic reactions in the general population is about 1 per 2.5 million people (3). In the hospitalized population, where exposure to allergenic substances is more common, the incidence may be as high as 1 per 1,700 patients (4). Other less severe forms of hypersensitivity reactions occur with even greater frequency. Accordingly, familiarity with hypersensitivity reactions, especially anaphylaxis, is extremely important in caring for critically ill patients.

Keywords

Hypersensitivity Reaction Allergy Clin Immunol Anaphylactic Reaction Anaphylactoid Reaction Systemic Mastocytosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bochner BS, Lichtenstein LM. Anaphylaxis. N Engl J Med 1991; 324: 1785–90.Google Scholar
  2. 2.
    Cohen SG. The pharaoh and the wasp. Allergy Proc 1989; 10: 149–51.PubMedCrossRefGoogle Scholar
  3. 3.
    Terr AI. Anaphylaxis & Urticaria. In: Stites DP, Terr AI, Parslow TG, eds. Medical Immunology, 9th ed. Stamford, CT: Apleton & Lange, 1997.Google Scholar
  4. 4.
    Boston Collaborative Drug Surveillance Program. Drug-induced anaphylaxis. JAMA 1973; 224: 613–5.CrossRefGoogle Scholar
  5. 5.
    Terr Al. Mechanisms of Hypersensitivity. In: Stites DP, Terr AI, Parslow TG, eds. Medical Immunology, 9th ed. Stamford, CT: Appleton & Lange, 1997.Google Scholar
  6. 6.
    Costa JJ, Weller PF, Galli SJ. The cells of the allergic response: mast cells, basophils and eosinophils. JAMA 1997; 278: 1815–22.PubMedCrossRefGoogle Scholar
  7. 7.
    Galli SJ, Costa JJ. Mast cell-leukocyte cytokine cascades in allergic inflammation. Allergy 1995; 50: 851–62.PubMedCrossRefGoogle Scholar
  8. 8.
    Beltrani VS. The clinical spectrum of atopic dermatitis. J Allergy Clin Immunol 1999; 104: S8798.Google Scholar
  9. 9.
    deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA 1997; 278: 1895906.Google Scholar
  10. 10.
    Withington DE. Allergy, anaphylaxis and anaesthesia. Can J Anaesth 1994; 41: 1133–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Clarke RS, Watkins J. Drugs responsible for anaphylactoid reactions in anaesthesia in the United Kingdom. Ann Fr Anesth Reanim 1993; 12: 105–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Kraske GK, Shinaberger JH, Klaustermeyer WB. Severe hypersensitivity reaction during hemodialysis. Ann Allergy Asthma Immunol 1997; 78: 217–20.PubMedCrossRefGoogle Scholar
  13. 13.
    Orfan N, Patterson R, Dykewicz MS. Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema. JAMA 1990; 264: 1287–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Wong S, Dykewicz MS, Patterson R. Idiopathic anaphylaxis. A clinical summary of 175 patients. Arch Intern Med 1990; 150: 1323–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Horrow JC. Protamine: a review of its toxicity. Anesth Analg 1985; 64: 348–61.PubMedCrossRefGoogle Scholar
  16. 16.
    Weiss ME, Nyhan D, Peng ZK, Horrow JC, Lowenstein E, Hirshman C, Adkinson NF Jr. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med 1989; 320: 886–92.PubMedCrossRefGoogle Scholar
  17. 17.
    Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977; 1: 466–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Dieterich HJ, Kraft D, Sirtl C, Laubenthal H, Schimetta W, Polz W, Gerlach E, Peter K. Hydroxyethyl starch antibodies in humans: incidence and clinical relevance. Anesth Analg 1998; 86: 1123–6.PubMedGoogle Scholar
  19. 19.
    Cohan RH, Leder RA, Ellis JH. Treatment of adverse reactions to radiographic contrast media in adults. Radiol Clin North Am 1996; 34: 1055–76.PubMedGoogle Scholar
  20. 20.
    Roizen MF, Levy JH, Moss J. Anaphylactic and Anaphylactoid Reactions. In: Hall JB, Schmidt GA, Wood LD, eds. Principles of Critical Care, 2nd ed. New York: McGraw-Hill, 1998.Google Scholar
  21. 21.
    Wyatt R. Anaphylaxis. How to recognize, treat, and prevent potentially fatal attacks. Postgrad Med 1996;100: 89–90, 96–9.Google Scholar
  22. 22.
    Silverman HJ, Van Hook C, Haponik EF. Hemodynamic changes in human anaphylaxis. Am J Med 1984; 77: 341–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Carlson RW, Schaeffer RC Jr, Puri VK, Brennan AP, Weil MH. Hypovolemia and permeability pulmonary edema associated with anaphylaxis. Crit Care Med 1981; 9: 883–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Booth BH, Patterson R. Electrocardiographic changes during human anaphylaxis. JAMA 1970; 211: 627–31.PubMedCrossRefGoogle Scholar
  25. 25.
    Fisher MM, Baldo BA. Mast cell tryptase in anaesthetic anaphylactoid reactions. Br J Anaesth 1998; 80: 26–29.PubMedCrossRefGoogle Scholar
  26. 26.
    Schwartz LB, Bradford TR, Rouse C, Irani AM, Rasp G, Van der Zwan JK, Van der Linden PW. Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol 1994; 14: 190–204.PubMedCrossRefGoogle Scholar
  27. 27.
    Levy JH. Anaphylactic Reactions in Anesthesia and Intensive Care, 2nd ed. Boston, MA: Butterworth-Heinemann, 1992.Google Scholar
  28. 28.
    Christie PE, Tagari P, Ford-Hutchinson AW, Charlesson S, Chee P, Ann JP, Lee TH. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991; 143: 1025–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Lieberman P. Distinguishing anaphylaxis from other serious disorders. J Respir Dis 1995; 16: 4 1120.Google Scholar
  30. 30.
    Barach EM, Nowak RM, Lee TG, Tomlanovich MC. Epinephrine for treatment of anaphylactic shock JAMA 1984; 251: 2118–22.Google Scholar
  31. 31.
    Project Team of The Resuscitation Council (UK). Emergency medical treatment of anaphylactic reactions. Resuscitation 1999; 41: 93–9.CrossRefGoogle Scholar
  32. 32.
    Kalinen M. Hypotheses on the contribution of late-phase allergic responses to the understanding and treatment of allergic diseases. J Allergy Clin Immunol 1984; 73: 311–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Lang DM. Anaphylactoid and anaphylactic reactions. Hazards of beta-blockers. Drug Saf 1995; 12: 299–304.Google Scholar
  34. 34.
    Toogood JH. Risk of anaphylaxis in patients receiving beta-blocker drugs. J Allergy Clin Immunol 1988; 81: 1–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Tanz RD, Kettelkamp N, Hirshman CA. The effect of calcium on cardiac anaphylaxis in guinea-pig Langendorff heart preparations. Agents Actions 1985; 16: 415–24.PubMedCrossRefGoogle Scholar
  36. 36.
    Ernst ME, Graber MA. Methylxanthine use in anaphylaxis: what does the evidence tell us? Ann Pharmacother 1999; 33: 1001–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Lieberman P. Anaphylactoid reactions to radiocontrast material. Immunol Allergy Clin North Am 1992; 12: 649–70.Google Scholar
  38. 38.
    Golden DB. Practical considerations in venom immunotherapy. Allergy Asthma Proc 1997; 18: 79–83.PubMedCrossRefGoogle Scholar
  39. 39.
    Hung OR, Bands C, Laney G, Drover D, Stevens S, MacSween M. Drug allergies in the surgical population. Can J Anaesth 1994; 41: 1149–55.PubMedCrossRefGoogle Scholar
  40. 40.
    Anne S, Reisman RE. Risk of administering cephalosporin antibiotics to patients with histories of penicillin allergy. Ann Allergy Asthma Immunol 1995; 74: 167–70.PubMedGoogle Scholar
  41. 41.
    Garrelts JC, Peterie JD. Vancomycin and the “red man’s syndrome. ” N Engl J Med 1985; 312: 245.PubMedGoogle Scholar
  42. 42.
    Polk RE, Healy DP, Schwartz LB, Rock DT, Garson ML, Roller K. Vancomycin and the red-man syndrome: phannacodynamics of histamine release. J Infect Dis 1988; 157: 502–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Renz CL, Thurn JD, Finn HA, Lynch JP, Moss J. Antihistamine prophylaxis permits rapid vancomycin infusion. Crit Care Med 1999; 27: 1732–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Holzman RS. Latex allergy: an emerging operating room problem. Anesth Analg 1993; 76: 635–41.PubMedCrossRefGoogle Scholar
  45. 45.
    Kelly KJ, Walsh-Kelly CM. Latex allergy: a patient and health care system emergency. Ann Emerg Med 1998; 32: 723–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Lebenbom-Mansour MH, Oesterle JR, Ownby DR, Jeunet MK, Post SK, Zaglaniczy K. The incidence of latex sensitivity in ambulatory surgical patients: a correlation of historical factors with positive serum immunoglobin E levels. Anesth Analg 1997; 85: 44–9.Google Scholar
  47. 47.
    Brown, RH, Schauble JF, Hamilton RG. Prevalence of latex allergy among anesthesiologists: identification of sensitized but asymptomatic individuals. Anesthesiology 1998; 89: 292–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Yunginger JW. Allergy to natural rubber latex. Minn Med 1998; 81: 27–30.PubMedGoogle Scholar
  49. 49.
    Lagier F, Vervloet D, Lhermet I, Poyen D, Charpin D. Prevalence of latex allergy in operating room nurses. J Allergy Clin Immunol 1992; 90: 319–22.PubMedCrossRefGoogle Scholar
  50. 50.
    Mehra P, Hunter MJ. Latex allergy: a review of considerations for the oral and maxillofacial surgeon. J Oral Maxillofac Surg 1998; 56: 1426–30.PubMedCrossRefGoogle Scholar
  51. 51.
    Vyas GN, Holmdahl L, Perkins HA, Fudenberg HH. Serologic specificity of human anti-IgA and its significance in transfusion. Blood 1969; 34: 573–81.PubMedGoogle Scholar
  52. 52.
    Schmidt AP, Taswell HF, Gleich GJ. Anaphylactic transfusion reactions associated with anti-IgA antibody. N Engl J Med 1969; 280: 188–93.PubMedCrossRefGoogle Scholar
  53. 53.
    Fisher MM, Baldo BA. The incidence and clinical features of anaphylactic reactions during anesthesia in Australia. Ann Fr Anesth Reanim 1993; 12: 97–104.PubMedCrossRefGoogle Scholar
  54. 54.
    Fisher MM, More DG. The epidemiology and clinical features of anaphylactic reactions in anaesthesia. Anaesth Intensive Care 1981; 9: 226–34.PubMedGoogle Scholar
  55. 55.
    McKinnon RP, Wildsmith JA. Histaminoid reactions in anaesthesia Br J Anaesth 1995; 74: 217–28.CrossRefGoogle Scholar
  56. 56.
    Baldo BA, Fisher MM. Substituted ammonium ions as allergenic determinants in drug allergy. Nature 1983; 306: 262–4.PubMedCrossRefGoogle Scholar
  57. 57.
    Laxenaire MC, Mata-Bermejo E, Moneret-Vautrin DA, Gueant JL. Life-threatening anaphylactoid reactions to propofol. Anesthesiology 1992; 77: 275–80.PubMedCrossRefGoogle Scholar
  58. 58.
    Nagel JE, Fuscaldo TT, Fireman P. Paraben allergy. JAMA 1977; 237: 1594–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Maged S. Mikhail
    • 1
  • Delbert R. Black
    • 2
  1. 1.University of Southern CaliforniaLos AngelesUSA
  2. 2.Massachusetts General HospitalBostonUSA

Personalised recommendations